Therapy Areas: Inflammatory Diseases
Sitryx launches for development of disease modifying therapeutics in immunometabolism
9 October 2018 -

Sitryx, a new biopharmaceutical company, has launched USD30m fundraising for the development of disease modifying therapeutics in immunometabolism, a fast-emerging area of investigation into the role of metabolic pathways in immune cell function, it was reported yesterday.

The company was founded with seed funding from SV Health investors and raised a total of USD30m from a syndicate of specialist international healthcare investors co-led by SV Health Investors and Sofinnova Partners, and which also included Longwood Fund and the global healthcare company, GSK.

The investment will be utilised to develop disease-modifying therapies in immuno-oncology and immuno-inflammation.

Login
Username:

Password: